scPharmaceuticals Inc. - Common Stock (SCPH)
Frequently Asked Questions About scPharmaceuticals Inc. - Common Stock (SCPH)
How can investors learn more about scPharmaceuticals?
Investors can learn more about scPharmaceuticals by visiting the company’s official website, where they can find detailed information about its products, pipeline, financial performance, and investor relations. Additionally, they may follow the company on social media platforms and read press releases and SEC filings for updates.
How does scPharmaceuticals engage with patients and stakeholders?
scPharmaceuticals engages with patients and stakeholders through various initiatives, including patient education programs, partnership with healthcare providers, and participation in conferences and industry events. The company actively seeks feedback to understand patient needs and improve its products and services.
How does scPharmaceuticals ensure drug safety?
scPharmaceuticals is committed to ensuring drug safety by adhering to rigorous regulatory standards set by agencies such as the FDA. The company conducts comprehensive preclinical studies and clinical trials to assess the safety and efficacy of its products, while also implementing quality control measures throughout the manufacturing process.
How does scPharmaceuticals handle regulatory approvals?
scPharmaceuticals navigates regulatory approvals by collaborating closely with regulatory agencies like the FDA. The company prepares and submits comprehensive data packages that include results from preclinical and clinical studies to demonstrate the safety and efficacy of its products before seeking marketing authorization.
Is scPharmaceuticals publicly traded?
Yes, scPharmaceuticals Inc. is publicly traded on the NASDAQ stock exchange under the ticker symbol SCPH. The company went public in 2018, offering investors the opportunity to participate in its growth and development within the biopharmaceutical sector.
What are scPharmaceuticals' main products?
scPharmaceuticals' main products include Furoscix, an injectable formulation of furosemide for the treatment of heart failure, and other pipeline candidates targeting various medical conditions. These products are designed to provide alternative delivery options and improve the quality of life for patients requiring long-term medication.
What are some recent developments at scPharmaceuticals?
Recent developments at scPharmaceuticals often include advancements in clinical trials, product launches, and strategic partnerships. To stay informed, stakeholders can check the company’s website and subscribe to press releases for the latest news related to its operations and product offerings.
What are the company's key partnerships?
scPharmaceuticals has established several strategic partnerships with various healthcare organizations, research institutions, and pharmaceutical companies. These collaborations aim to enhance its research capabilities, accelerate product development, and leverage additional resources for commercialization and distribution.
What challenges does scPharmaceuticals face?
scPharmaceuticals faces various challenges, including the competitive landscape of the biopharmaceutical industry, regulatory hurdles, the need for substantial funding for R&D, and the complexities of commercializing innovative medical products. Addressing these challenges is crucial for the company’s growth and success.
What distinguishes scPharmaceuticals from its competitors?
scPharmaceuticals distinguishes itself from competitors through its innovative drug delivery systems and a strong focus on enhancing patient convenience. The company’s proprietary technologies aim to provide superior alternatives to traditional injectable treatments, enhancing patient adherence, and improving overall outcomes.
What does scPharmaceuticals Inc. do?
scPharmaceuticals Inc. is a biopharmaceutical company that focuses on developing and commercializing innovative injectable pharmaceuticals for the treatment of diseases. Their primary goal is to enhance patient outcomes by enabling more effective, convenient, and cost-efficient delivery of medications through their proprietary drug delivery system.
What is Furoscix?
Furoscix is scPharmaceuticals' lead product, which is an investigational drug designed for the subcutaneous administration of furosemide, a diuretic commonly used in the management of heart failure. The product aims to allow patients to receive treatment in a more comfortable setting, such as their home, rather than in a clinical setting.
What is scPharmaceuticals' commitment to research and development?
scPharmaceuticals is deeply committed to research and development (R&D) as a core component of its strategy. The company allocates significant resources to R&D to foster innovation in drug formulations and delivery systems, ensuring that its products meet the evolving needs of patients and healthcare professionals.
What is the company’s vision for the future?
scPharmaceuticals envisions a future where innovative drug delivery systems become a standard practice in the treatment of chronic diseases. The company aims to expand its product pipeline, enhance patient experiences, and drive advancements in healthcare that contribute to improved patient outcomes and reduced overall costs.
What is the target market for scPharmaceuticals' products?
The target market for scPharmaceuticals' products primarily includes patients with chronic conditions that require injectable treatments, such as heart failure. By focusing on enhancing the delivery and administration of these medications, the company aims to improve patient adherence and outcomes within this substantial market.
What stage is scPharmaceuticals' product pipeline currently in?
As of now, scPharmaceuticals' product pipeline includes both commercialized products like Furoscix and several candidates in various stages of development. The company continues to conduct clinical trials to evaluate the efficacy and safety of its products while seeking to expand its portfolio with new therapeutic options.
When was scPharmaceuticals Inc. founded?
scPharmaceuticals Inc. was founded in 2014. The company was established with the vision of transforming the delivery of injectable drugs, particularly for patients with chronic conditions, by developing advanced formulations and delivery mechanisms that improve patient adherence and outcomes.
Where is scPharmaceuticals Inc. headquartered?
scPharmaceuticals Inc. is headquartered in Framingham, Massachusetts. The location was chosen as it offers proximity to numerous research institutions and healthcare resources, fostering collaboration and innovation in the biopharmaceutical sector.
Who are the key executives at scPharmaceuticals?
Key executives at scPharmaceuticals include leadership with extensive experience in the biopharmaceutical industry. This typically features positions such as the Chief Executive Officer, Chief Financial Officer, and other high-level executives who guide the company's strategic direction and operational initiatives.
What is the current price of scPharmaceuticals Inc. - Common Stock?
The current price of scPharmaceuticals Inc. - Common Stock is 5.500
When was scPharmaceuticals Inc. - Common Stock last traded?
The last trade of scPharmaceuticals Inc. - Common Stock was at 4:00 pm EDT on August 29th, 2025
What is the market capitalization of scPharmaceuticals Inc. - Common Stock?
The market capitalization of scPharmaceuticals Inc. - Common Stock is 196.73M
How many shares of scPharmaceuticals Inc. - Common Stock are outstanding?
scPharmaceuticals Inc. - Common Stock has 35.77M shares outstanding.